Literature DB >> 22914967

Role of 18F-fluoride PET/CT in the assessment of multiple myeloma: initial experience.

Yuji Nishiyama1, Ukihide Tateishi, Kazuya Shizukuishi, Ayako Shishikura, Etsuko Yamazaki, Hiroto Shibata, Tomohiro Yoneyama, Yoshiaki Ishigatsubo, Tomio Inoue.   

Abstract

PURPOSE: The aim of this study was to report our early experience with (18)F-fluoride PET/CT for detecting lesions and evaluate the usefulness of this modality in the assessment of multiple myeloma (MM).
MATERIALS AND METHODS: (18)F-fluoride PET/CT and (99m)Tc-MDP bone scintigraphy (BS) studies from 7 myeloma patients (4 male and 3 female, mean age 55 years) diagnosed according to standard criteria were reviewed retrospectively. Two reviewers visually and quantitatively analyzed the images and recorded their findings after reaching a consensus. Diagnostic certainty regarding the presence or absence of myeloma lesions was evaluated according to the reference standard consisting of whole-body magnetic resonance imaging and whole-body X-ray.
RESULTS: A total of 93 affected areas were definite according to the reference standard. Of these, 83 affected areas (89 %) were identified on (18)F-fluoride PET/CT, whereas 54 affected areas (58 %) were found on BS. Mean SUVmax in the affected areas was 9.8 ± 3.2 (standard deviation) ranging from 5.0 to 21.2. A total of s17 lesions with bone fracture were also detected by (18)F-fluoride PET/CT and 2 lesions (12 %) were negative on BS.
CONCLUSION: Our result showed that (18)F-fluoride PET was a possible modality to detect areas of lesions in patients with MM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22914967     DOI: 10.1007/s12149-012-0647-7

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  10 in total

1.  PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.

Authors:  Christos Sachpekidis; Hartmut Goldschmidt; Dirk Hose; Leyun Pan; Caixia Cheng; Klaus Kopka; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

2.  Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.

Authors:  Christos Sachpekidis; Jens Hillengass; Hartmut Goldschmidt; Hoda Anwar; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

3.  Impact of Nonosseous Findings on (18)F-NaF PET/CT in a Patient with Ductal Breast Carcinoma.

Authors:  Serkan Kuyumcu; Isik Adalet; Emine Goknur Isik; Seher Nilgun Unal
Journal:  Nucl Med Mol Imaging       Date:  2013-09-19

4.  Sodium 18F-fluoride PET/CT of bone, joint, and other disorders.

Authors:  Hossein Jadvar; Bhushan Desai; Peter S Conti
Journal:  Semin Nucl Med       Date:  2015-01       Impact factor: 4.446

5.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

6.  Prognostic significance of 18F-sodium fluoride in newly diagnosed multiple myeloma patients.

Authors:  Mahdi Zirakchian Zadeh; Siavash Mehdizadeh Seraj; Brian Østergaard; Stephanie Mimms; William Y Raynor; Mahmoud Aly; Austin J Borja; Leila S Arani; Oke Gerke; Thomas J Werner; Hongming Zhuang; Mona-Elisabeth Revheim; Niels Abildgaard; Poul Flemming Høilund-Carlsen; Abass Alavi
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-08-25

7.  Is 99m Tc-methylene diphosphonate bone scintigraphy a sensitive method for detecting bone lesions in multiple myeloma?

Authors:  Mohsen Vakili Sadeghi; Sadegh Sedaghat
Journal:  Caspian J Intern Med       Date:  2018

8.  Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?

Authors:  Christos Sachpekidis; Annette Kopp-Schneider; Maximilian Merz; Anna Jauch; Marc-Steffen Raab; Hartmut Goldschmidt; Antonia Dimitrakopoulou-Strauss
Journal:  Cancers (Basel)       Date:  2020-05-23       Impact factor: 6.639

9.  Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma.

Authors:  Y Wang; A J Yee; C Sirard; S Landau; N Raje; U Mahmood
Journal:  Blood Cancer J       Date:  2017-10-06       Impact factor: 11.037

Review 10.  Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.

Authors:  Christos Sachpekidis; Hartmut Goldschmidt; Antonia Dimitrakopoulou-Strauss
Journal:  Molecules       Date:  2019-12-29       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.